Lineage Cell Therapeutics (LCTX) Gains from Investment Securities (2018 - 2026)

Lineage Cell Therapeutics' Gains from Investment Securities history runs 5 years deep, the most recent figure standing at -$2.3 million for Q1 2026.

• On a quarterly basis, Gains from Investment Securities fell 0.82% year-over-year to -$2.3 million in Q1 2026; TTM through Mar 2026 was $35.7 million, a 905.5% increase from a year earlier, with the FY2025 full-year figure at $35.7 million, up 1778.9% from the prior year.
• Gains from Investment Securities slipped to -$2.3 million in Q1 2026 per LCTX's latest filing, from -$1.3 million in the prior quarter.
• Across five years, Gains from Investment Securities topped out at $26.6 million in Q3 2025 and bottomed at -$2.3 million in Q1 2026.
• The 3-year median for Gains from Investment Securities is -$1.7 million (2024), against an average of $5.2 million.
• Across the five-year window, Gains from Investment Securities surged 40.55% in 2025 and declined 0.82% in 2026, its largest moves.
• Year by year, Gains from Investment Securities stood at -$2.1 million in 2024, then jumped by 40.55% to -$1.3 million in 2025, then sank by 83.72% to -$2.3 million in 2026.
• Per Business Quant, the three latest LCTX Gains from Investment Securities figures stand at -$2.3 million (Q1 2026), -$1.3 million (Q4 2025), and $26.6 million (Q3 2025).